Meet Our Interns!

We are so excited to welcome our 8 new interns for our 2022 internship program – learn a little bit more about each the newest additions to COTA.
COTA Research Showcased High Concordance Rate Between Real-World Physician Response Assessment & the 2017 European LeukemiaNet (ELN) Criteria for Acute Myeloid Leukemia at EHA2022

COTA researchers and collaborators’s recent abstract in the European Hematology Association’s library, found that overall agreement between response categories was 65.1% among AML data.
Creating a Clear Path to Precision Oncology with Real-World Data

ViVE 2022 brought together thought leaders addressing key disparities and the future of healthcare. Our own C.K. Wang, alongside expert oncologists and technology innovators stressed the need for understanding what “precision oncology” really is.
Leading COTA into the Next Chapter of Data-Driven Precision Oncology

I’m delighted to be leading COTA at this pivotal moment in history, when precision oncology and data science are advancing together at lightning speed. By working with partners across the healthcare continuum, we can guide cancer patients and their families down the path to clear, safe, personalized, and effective cancer care.
Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

In this article in the scientific journal Blood Reviews, COTA researchers and collaborators share their views on the many sources of RWD and how to assess fit-for-purpose for use in RWE generation. They also review promising use cases for RWD, particularly for hematologic malignancies.
To Help Accelerate Development of Cancer Treatments with Real-World Data, COTA Welcomes Kevin Schweikert as Vice President, Life Sciences

COTA is pleased to announce Kevin Schweikert has joined the company as vice president, life sciences. With more than 20 years of experience in life sciences business development, Kevin has partnered with the most innovative pharmaceutical companies in the business, and the vendors these companies turn to for real-world data and analytics.
Real-World Data is Essential for Illuminating and Addressing Disparities in Care

RWD can help us address one of the most challenging systemic issues in healthcare: disparities in health outcomes perpetuated by uneven access to services and the unconscious bias of humans and technology
Patient-Centered Drug Development Leads the Way in 2022

This will be the year that patient centricity drives drug development and care delivery decisions.
Study: 83% of Oncologists Believe Real-World Data Is Critical to Accelerating Cancer Research and Treatment

Oncologists believe it is important for all clinical trials to include a real-world data component, and the overwhelming majority would urge pharmaceutical companies and cancer research groups to use real-world data in all clinical trials as well.
Real-World Data Champion Robert Califf Nominated for FDA Commissioner

Dr. Califf is a staunch advocate for the use of real-world data (RWD) and real-world evidence (RWE) in the clinical trial ecosystem, with a long history of leveraging RWD and RWE to transform the life sciences community.